IGM Biosciences Analyst Ratings
BofA Securities Initiates IGM Biosciences(IGMS.US) With Hold Rating
J.P. Morgan Upgrades IGM Biosciences(IGMS.US) to Hold Rating
Truist Securities Maintains Hold on IGM Biosciences, Lowers Price Target to $2
Stifel Downgrades IGM Biosciences to Hold, Lowers Price Target to $2.5
Analysts Offer Insights on Healthcare Companies: IGM Biosciences (IGMS) and Abivax SA Sponsored ADR (ABVX)
Guggenheim Downgrades IGM Biosciences(IGMS.US) to Hold Rating
RBC Downgrades IGM Biosciences to Sector Perform From Outperform, Slashes Price Target to $1.50 From $20, Keeps Speculative Risk Qualifier
IGM Biosciences Cut to Market Perform From Outperform by BMO Capital
IGM Biosciences Analyst Ratings
IGM Biosciences Downgraded to Hold From Buy at Stifel
Morgan Stanley Downgrades IGM Biosciences(IGMS.US) to Sell Rating, Cuts Target Price to $2
BMO Capital Initiates Coverage On IGM Biosciences With Outperform Rating, Announces Price Target of $21
BMO Capital Initiates IGM Biosciences(IGMS.US) With Buy Rating, Announces Target Price $21
IGM Biosciences Analyst Ratings
Stifel Maintains IGM Biosciences(IGMS.US) With Buy Rating, Raises Target Price to $27
RBC Capital Reaffirms Their Buy Rating on IGM Biosciences (IGMS)
IGM Biosciences Is Maintained at Outperform by RBC Capital
IGM Biosciences Analyst Ratings
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), IGM Biosciences (IGMS)